Diabetic retinopathy: Battling the global epidemic

Investigative Ophthalmology and Visual Science

Volumn 57, Issue 15, 2016, Pages 6669-6682

  Das, Arup ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Blood retinal barrier; Diabetes mellitus; Diabetic retinopathy; Endothelial cells; Pericytes; Retina

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DNA METHYLTRANSFERASE; HEMOGLOBIN A1C; KALLIKREIN INHIBITOR; MICRORNA; PEGAPTANIB; RANIBIZUMAB; REACTIVE OXYGEN METABOLITE; SIRTUIN; STREPTOZOCIN; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN;

ARTICLE; BASEMENT MEMBRANE; BIOAVAILABILITY; BLOOD RETINA BARRIER; CELL JUNCTION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; EPIDEMIC; EPIGENETICS; HUMAN; INFLAMMATION; LASER COAGULATION; MICROGLIA; NEUROPROTECTION; NEXT GENERATION SEQUENCING; OPTICAL COHERENCE TOMOGRAPHY; PERICYTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTORECEPTOR; PRIORITY JOURNAL; SCANNING LASER OPHTHALMOSCOPY; STEM CELL TRANSPLANTATION; TELEMEDICINE; VITRECTOMY; GLOBAL HEALTH; RISK FACTOR;

DIABETIC RETINOPATHY; EPIDEMICS; GLOBAL HEALTH; HUMANS; RISK FACTORS;

EID: 85006416156     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.16-21031     Document Type: Article

References (86)

1. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.
2. Yau JW, Rogers SL, Kawasaki R, et al.; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-564.
3. Huang OS, Tay WT, Tai ES, et al. Lack of awareness amongst community patients with diabetes and diabetic retinopathy: the Singapore Malay Eye Study. Ann Acad Med Singapore. 2009;38:1048-1055.
4. Anjana RM, Shanthi Rani CS, Deepa M, et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10-year follow-up of the Chennai Urban Rural Epidemiology Study (CURES). Diabetes Care. 2015;38: 1441-1448.
5. Raman R, Rani PK, Gnanamoorthy P, et al. Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SN-DREAMS Report no. 8). Acta Diabetol. 2010;47:209-215.
6. Lachin JM, Genuth S, Nathan DM, et al. DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes. 2008;57:995-1001.
7. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008;205:2409-2417.
8. Giacco F, Du X, Carrat´u A, et al. GLP-1 Cleavage product reverses persistent ROS generation after transient hyperglycemia by disrupting an ROS-generating feedback loop. Diabetes. 2015;64:3273-3284.
9. Santos JM, Kowluru RA. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Invest Ophthalmol Vis Sci. 2011;52:8791-8798.
10. Kowluru RA, Kowluru A, Mishra M, Kumar B. Oxidative stress and epigenetic modifications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res. 2015;48:40-61.
11. McAuley AK, Dirani M, Wang JJ, Connell PP, Lamoureux EL, Hewitt AW. A genetic variant regulating miR-126 is associated with sight threatening diabetic retinopathy. Diab Vasc Dis Res. 2015;12:133-138.
12. Wang Q, Bozack SN, Yan Y, Boulton ME, Grant MB, Busik JV. Regulation of retinal inflammation by rhythmic expression of MiR-146a in diabetic retina. Invest Ophthalmol Vis Sci. 2014; 55:3986-3994.
13. Cowan C, Muraleedharan CK, O’Donnell JJ III, et al. Micro-RNA-146 inhibits thrombin-induced NF-kappaB activation and subsequent inflammatory responses in human retinal endothelial cells. Invest Ophthalmol Vis Sci. 2014;55:4944-4951.
14. Zhao R, Qian L, Jiang L. miRNA-dependent cross-talk between VEGF and Ang-2 in hypoxia-induced microvascular dysfunction. Biochem Biophys Res Commun. 2014;452:428-435.
15. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
16. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007;56:224-230.
17. Chan CK, Mohamed S, Lee VY, Lai TY, Shanmugam MP, Lam DS. Intravitreal dexamethasone for diabetic macular edema: a pilot study. Ophthal Surg Lasers Imaging. 2010;41:26-30.
18. El-Asrar AM. Role of inflammation in the pathogenesis of diabetic retinopathy. Middle East Afr J Ophthalmol. 2012;19: 70-74.
19. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:1366-1369.
20. Suzuki Y, Nakazawa M, Suzuki K, et al. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011;55:256-263.
21. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-1452.
22. Zheng L, Howell SJ, Hatala DA, et al. Salicylate-based antiinflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes. 2007;56:337-345.
23. Schwartzman ML, Iserovich P, Gotlinger K, et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes. 2010;59: 1780-1788.
24. Cahoon JM, Rai RR, Carroll LS, et al. Intravitreal AAV2.COMPAng1 prevents neurovascular degeneration in a murine model of diabetic retinopathy. Diabetes. 2015;64:4247-4259.
25. Du Y, Veenstra A, Palczewski K, Kern TS. Photoreceptor cells are major contributors to diabetes-induced oxidative stress and local inflammation in the retina. Proc Natl Acad Sci U S A. 2013;110:16586-16591.
26. Cerani A, Tetreault N, Menard C, et al. Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1. Cell Metab. 2013;18: 505-518.
27. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Ann Rev Pharmacol Toxicol. 2007;47:89-116.
28. Xu Z, Wei Y, Gong J, et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 2014;57:204-213.
29. Xu Z, Cho H, Hartsock MJ, et al. Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusion. J Neurochem. 2015;133:233-241.
30. Zhong Q, Mishra M, Kowluru RA. Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2013;54: 3941-3948.
31. Mishra M, Zhong Q, Kowluru RA. Epigenetic modifications of Keap1 regulate its interaction with the protective factor Nrf2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2014;55:7256-7265.
32. Mishra M, Zhong Q, Kowluru RA. Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression. Free Radic Biol Med. 2014;75:129-139.
33. Sun JK, Keenan HA, Cavallerano JD. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care. 2011;34:968-974.
34. Das A, Frank RN, Zhang NL, Turczyn TJ. Ultrastructural localization of extracellular matrix components in human retinal vessels and Bruch’s membrane. Arch Ophthalmol. 1990;108:421-429.
35. Antonelli-Orlidge A, Saunders KB, Smith SR, D’Amore PA. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci U S A. 1989;86:4544-4548.
36. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47:1953-1959.
37. Zhou Y, Wang Y, Tischfield M, et al. Canonical WNT signaling components in vascular development and barrier function. J Clin Invest. 2014;124:3825-3846.
38. Valdez CN, Arboleda-Velasquez JF, Amarnani DS, et al. Retinal microangiopathy in a mouse model of inducible mural cell loss. Am J Pathol. 2014;184:2618-2626.
39. Chronopoulos A, Trudeau K, Roy S, et al. High glucoseinduced altered basement membrane composition and structure increases trans-endothelial permeability: implications for diabetic retinopathy. Curr Eye Res. 2011;36:747-753.
40. Chronopoulos A, Tang A, Beglova E, et al. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. Diabetes. 2010;59:3159-3166.
41. Arden GB. The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment. Br J Ophthalmol. 2001;85:366-370.
42. Liu H, Tang J, Du Y, et al. Retinylamine benefits early diabetic retinopathy in mice. J Biol Chem. 2015;290:21568-21579.
43. Beli E, Dominguez JM II, Hu P, et al. CX3CR1 deficiency accelerates the development of retinopathy in a rodent model of type 1 diabetes. J Mol Med (Berl). 2016;94:1255-1265.
44. Chui TYP, Vannasdale DA, Burns SA. The use of forward scatter to improve retinal vascular imaging with an adaptive optics scanning laser ophthalmoscope. Biomed Opt Express. 2012;3:2537-2549.
45. Burns SA, Elsner AE, Chui TY, et al. In vivo adaptive optics microvascular imaging in diabetic patients without clinically severe diabetic retinopathy. Biomed Opt Express. 2014;5: 961-974.
46. Pinhas A, Razeen M, Dubow M, et al. Assessment of perfused foveal microvascular density and identification of nonperfused capillaries in healthy and vasculopathic eyes. Invest Ophthalmol Vis Sci. 2014;55:8056-8066.
47. Kita T, Clermont AC, Murugesan N, et al. Plasma kallikreinkinin system as a VEGF-independent mediator of diabetic macular edema. Diabetes. 2015;64:3588-3599.
48. Walia S, Clermont AC, Gao BB, Aiello LP, Feener EP. Vitreous proteomics and diabetic retinopathy. Semin Ophthalmol. 2010;25:289-294.
49. The ACCORD Study group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233044.
50. University Group Diabetes Program (UGDP). A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19(suppl 2):747-830.
51. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS Report No. 1. Arch Ophthalmol. 1985;10:1796-1806.
52. Sher A, Jones BW, Huie P, et al. Restoration of retinal structure and function after selective photocoagulation. J Neurosci. 2013;33:6800-6808.
53. Lavinsky D, Cardillo JA, Mandel Y, et al. Restoration of retinal morphology and residual scarring after photocoagulation. Acta Ophthalmol. 2013;91:e315-e323.
54. Lavinsky D, Sramek C, Wang J, et al. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina. 2014;34:87-97.
55. Aaberg TM, Abrams GW. Changing indications and techniques for vitrectomy in management of complications of diabetic retinopathy. Ophthalmology. 1987;94:775-779.
56. Elman MJ, Ayala A, Bressler NM, et al. Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122:375-381.
57. Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Ophthalmology. 2016;123:1351-1359.
58. Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122:1375-1394.
59. Rangasamy S, Srinivasan R, Maestas J, et al. A potential role of angiopoietin-2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52: 3784-3791.
60. Rangasamy S, McGuire PG, Franco Nitta C, et al. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One. 2014;9:e108508.
61. Shen J, Frye M, Lee BL, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014;124: 4564-4576.
62. Campochiaro PA, Sophie R, Tolentino M, et al. Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology. 2015;122:545-554.
63. Silva PS, Cavallerano JD, Tolls D, et al. Potential efficiency benefits of nonmydriatic ultrawide field retinal imaging in an ocular telehealth diabetic retinopathy program. Diabetes Care. 2014;37:50-55.
64. Parsons-Wingerter P, Radhakrishnan K, Vickerman MB, Kaiser PK. Oscillation of angiogenesis with vascular dropout in diabetic retinopathy by VESsel GENeration analysis (VESGEN). Invest Ophthalmol Vis Sci. 2010;51:498-507.
65. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/ progenitor cell principals. Blood. 2007;109:1801-1809.
66. Kusuyama T, Omura T, Nishiya D, et al. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci. 2006;102:96-102.
67. Dotta F, Sorrentino V. Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia. 2008;51:1296-1305.
68. Awad O, Jiao C, Ma N, Dunnwald M, Schatteman GC. Obese diabetic mouse environment differentially affects primitive and monocytic endothelial cell progenitors. Stem Cells. 2005; 23:575-583.
69. Jarajapu YP, Grant MB. The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res. 2010;106:854-869.
70. Loomans CJ, de Koning EJ, Staal FJ, et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes. 2004;53:195-199.
71. Busik JV, Tikhonenko M, Bhatwadekar A, et al. Diabetic retinopathy is associated with bone marrow neuropathy and a depressed peripheral clock. J ExpMed. 2009;206:2897-2906.
72. Hu P, Thinschmidt JS, Yan Y, et al. CNS inflammation and bone marrow neuropathy in type 1 diabetes. Am J Pathol. 2013; 183:1608-1620.
73. Hu P, Thinschmidt JS, Caballero S, et al. Loss of survival factors and activation of inflammatory cascades in brain sympathetic centers in type 1 diabetic mice. Am J Physiol Endocrinol Metab. 2015;308:E688-E698.
74. Yellowlees DJ, Bhatwadekar AD, Li Calzi S, et al. Bone marrow-CNS connections: implications in the pathogenesis of diabetic retinopathy. Prog Retin Eye Res. 2012;31:481-494.
75. Yang HJ, Ratnapriya R, Cogliati T, Kim JW, Swaroop A. Vision from next generation sequencing: multi-dimensional genomewide analysis for producing gene regulatory networks underlying retinal development, aging and disease. Prog Retin Eye Res. 2015;46:1-30.
76. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharmaceutics. 2013; 10:4676-4686.
77. Yu Y, Lau LC, Lo AC, Chau Y. Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study. Trans Vis Sci Tech. 2015; 4(2):5.
78. Park K, Chen Y, Hu Y, et al. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009;58:1902-1913.
79. Jin J, Zhou KK, Park K, et al. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci. 2011; 52:6230-6237.
80. Kannan S, Dai H, Navath RS, et al. Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med. 2012;4:130.
81. Evans SM, Kim K, Moore CE, et al. Molecular probes for imaging of hypoxia in the retina. Bioconjug Chem. 2014;25: 2030-2037.
82. Uddin MI, Evans SM, Craft JR, Marnett LJ, Uddin MJ, Jayagopal A. Applications of azo-based probes for imaging retinal hypoxia. ACS Med Chem Lett. 2015;6:445-449.
83. Poole KM, Nelson CE, Joshi RV, et al. ROS-responsive microspheres for on demand antioxidant therapy in a model of diabetic peripheral arterial disease. Biomaterials. 2015;41: 166-175.
84. Harris TJ, Green JJ, Fung PW, Langer R, Anderson DG, Bhatia SN. Tissue-specific gene delivery via nanoparticle coating. Biomaterials. 2010;31:998-1006.
85. Li H, Yu SS, Miteva M, et al. Matrix metalloproteinase responsive, proximity-activated polymeric nanoparticles for siRNA delivery. Adv Funct Mater. 2013;23:3040-3052.
86. Yu H, Popescu GK. Inhibition of GluN2A-containing Nmethyl-D-aspartate receptors by 2-naphthoic acid. Mol Pharmacol. 2013;84:541-550.